UNSPSC 51351910: Quinestradol

This classification denotes a therapeutic estrogen with the molecular formula C23H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 422L8173W8, chemically known as 3-(cyclopentyloxy)estra-1,3,5(10)-triene-16alpha,17beta-diol but generally known as quinestradol, which bears US NIH Compound Identifier 14431. European Medicines Agency schedules Quinestradol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10210MIG. The term QUINESTRADOL is an International Non-Proprietary Name.

UNSPSC 51351910 Quinestradol (Commodity) covers generic pharmaceutical products supplied through state and local cooperative purchasing vehicles, with recent activity focused on multi-source generic pharmaceuticals and over-the-counter products distributed across participating government facilities. State and local governments buy this code when establishing master agreements with pharmaceutical manufacturers for bulk supply of generic drugs, with pricing, product information, and supply-chain compliance as the primary evaluation factors. Issuing bodies soliciting under this code include state cooperative purchasing alliances that aggregate demand across multiple jurisdictions and participating agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent activity, with the alliance drawing participation from Oregon and other states.

MMCAP issued an RFP (S1070000015802) on January 20, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with all products available in the marketplace by May 15, 2026 and resulting contracts effective July 1, 2026. Evaluation is weighted heavily on price competitiveness (75 percent), with the remainder distributed across fixed pricing submission (10 percent), price format options including WAC-minus and net price structures (5 percent), EDI capability (5 percent), and administrative fee compliance (5 percent). Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain contractual relationships with at least two of the three authorized wholesalers, and carry professional liability and network security insurance of $2,000,000 each. The contract term is two years for new vendors with optional extensions at MMCAP's discretion, while incumbent vendors' amendments extend through June 30, 2028.